Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.
| Revenue (Most Recent Fiscal Year) | $310.20M |
| Net Income (Most Recent Fiscal Year) | $-51.09M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.35 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -7.41% |
| Net Margin (Trailing 12 Months) | -7.70% |
| Return on Equity (Trailing 12 Months) | -7.67% |
| Return on Assets (Trailing 12 Months) | -2.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.99 |
| Inventory Turnover (Trailing 12 Months) | 0.46 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.00 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.02 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.53M |
| Free Float | 45.27M |
| Market Capitalization | $2.03B |
| Average Volume (Last 20 Days) | 0.31M |
| Beta (Past 60 Months) | 0.77 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 84.50% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |